

***Centers for Disease Control and Prevention  
Lipid Standardization Program  
2022***

*certifies the*

**Medpace Pharmaceutical Sciences (Shanghai) Co., Ltd  
INT-418**

*This laboratory, under the direction of Dr. Tan Paul, has successfully met precision and accuracy criteria for standardization by the Centers for Disease Control and Prevention Lipid Standardization Program during the Second Quarter of 2022 for the following analytical systems:*

<b>Instrument</b>	<b>Analyte</b>	<b>Method</b>
<b>Beckman AU 5800</b>	<b>TC</b>	<b>601 - Enzymatic</b>
<b>Beckman AU 5800</b>	<b>TG</b>	<b>602 - Enzymatic (Non Blanked)</b>
<b>Beckman AU 5800</b>	<b>HDLC</b>	<b>605 - Dextran Sulfate MW 50,000/Mg</b>



Hubert Vesper, PhD  
Director of CDC Clinical Standardization Programs

